These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Patient group seeks overhaul of FDA clinical trial system in court. Hede K J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242 [No Abstract] [Full Text] [Related]
5. Does your clinical investigator understand the consequences of non-compliance? Donato BJ; Gibson TR Qual Assur; 1999; 7(3):135-45. PubMed ID: 11033739 [TBL] [Abstract][Full Text] [Related]
6. U.S. FDA regulatory challenges and review. Lepore P Qual Assur; 1994 Jun; 3(2):131-7. PubMed ID: 7804628 [No Abstract] [Full Text] [Related]
7. Researchers left to guess at outcomes of most cancer clinical trials. Twombly R J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774 [No Abstract] [Full Text] [Related]
8. Boost bottom line with research nurse. ED Manag; 2001 Dec; 13(12):140-2. PubMed ID: 11769137 [TBL] [Abstract][Full Text] [Related]
9. The role of data audits in detecting scientific misconduct. Results of the FDA program. Shapiro MF; Charrow RP JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109 [TBL] [Abstract][Full Text] [Related]
10. Federal drug agency gets flack about human subjects protections in clinical trials. Beckman M J Natl Cancer Inst; 2008 Jan; 100(2):90-1. PubMed ID: 18182612 [No Abstract] [Full Text] [Related]
11. The clinical nurse specialist as research coordinator in clinical drug trials. Raybuck JA Clin Nurse Spec; 1997 Jan; 11(1):15-9. PubMed ID: 9233133 [TBL] [Abstract][Full Text] [Related]
12. Food and Drug Administration requirements for approval of new anticancer drugs. Johnson JR; Temple R Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094 [TBL] [Abstract][Full Text] [Related]
13. The "weak link" in new drug research. Feldmann EG J Pharm Sci; 1983 May; 72(5):463. PubMed ID: 6864492 [No Abstract] [Full Text] [Related]
14. Scientific misconduct in investigational drug trials. Shapiro MF; Charrow RP N Engl J Med; 1985 Mar; 312(11):731-6. PubMed ID: 3974649 [No Abstract] [Full Text] [Related]
16. IRB/FDA requirements relevant to HIV/AIDS clinical trials in correctional settings. Cohen J; AIDS Read; 2001 Jan; 11(1):41-2. PubMed ID: 11215087 [TBL] [Abstract][Full Text] [Related]
17. Clinical research and the development of new devices: considerations for nurses. Lanter J Dimens Crit Care Nurs; 2007; 26(3):117-20. PubMed ID: 17440296 [TBL] [Abstract][Full Text] [Related]
18. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration. Bramstedt KA Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804 [TBL] [Abstract][Full Text] [Related]
19. FDA financial disclosure plan flops. Fox JL Biotechnology (N Y); 1995 Sep; 13(9):939-40. PubMed ID: 9678951 [No Abstract] [Full Text] [Related]
20. Clinical investigations with medical devices. New rules. Kennedy RS JAMA; 1981 May 22-29; 245(20):2052-5. PubMed ID: 7230401 [No Abstract] [Full Text] [Related] [Next] [New Search]